NCT06674863Recruiting
Addressing Health Literacy With a Tailored Survivorship Care Plan
Addressing Health Literacy With a Tailored Survivorship Care Plan to Improve Access in Underserved African American Prostate Cancer Patients
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 4 Nov 2024
- Start date
- 7 Nov 2025
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Emory University
- Diseases
- Prostate cancer
- NCT number
- NCT06674863
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 7 Nov 2025 to the primary completion date, 31 Dec 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Dementia or cognitive impairment per provider clinical assessment
- Recurrent prostate cancer after primary treatment
- Diagnosis of active second malignancy requiring treatment
Age
- Less than 18 years of age at the time of informed consent
Other
- Unable to give informed consent in the judgement of the patient's oncology provider
- Individuals who are not able to clearly understand English since the outcome measures require understanding of English
Who the study is looking for
- Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
- Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Hospital/Winship Cancer Institute Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| Atlanta VA Medical Center Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| Grady Memorial Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.